Research programme: tregitopes - EpiVax

Drug Profile

Research programme: tregitopes - EpiVax

Alternative Names: Albumin-tregitope; Epi-13

Latest Information Update: 24 Jul 2016

Price : $50

At a glance

  • Originator EpiVax
  • Developer EpiVax; Novozymes A/S
  • Class Immunoglobulin fragments; Peptides
  • Mechanism of Action Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypersensitivity; Type 1 diabetes mellitus
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Glycogen storage disease type II

Most Recent Events

  • 24 Jul 2016 Preclinical development in Type-1 diabetes mellitus and Hypersensitivity is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Chronic inflammatory demyelinating polyradiculoneuropathy in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Glycogen-storage-disease-type-II in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top